맞춤형 의학 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 페이즈별, 최종 용도별, 서비스별, 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Market Size & Trends:

The global personalized medicine outsourcing market size was estimated at USD 112.08 billion in 2024 and is projected to grow at a CAGR of 12.47% from 2025 to 2030. The increasing awareness regarding benefits of personalized medicine, increasing application of personalized medicine in various diseases, such as rare diseases, cancer, infectious diseases, and others, the requirement of specialized expertise, and the benefits of outsourcing the services are some of the major factors driving the market growth. The increasing prevalence of diseases such as chronic diseases, rare diseases and infectious diseases is further increasing the demand for these medicines as it offers enhanced patient outcomes. According to the American Cancer Society report, Cancer Facts & Figures 2023, cancer was expected to cause around 609,820 deaths in the U.S. in 2023 and was expected to diagnose over 1.9 people in the same year.

The applications of personalized medicine have significantly increased in cancer care, which is one of the major factors contributing to the market growth. Personalized medicine or precision medicine is utilized for several indications in oncology such as early detection of certain cancers, identifying people with higher cancer risk, evaluation of treatment alternatives, and effect of treatment on patient's health. As the burden of these diseases increase, the demand for personalized medicine is also anticipated to witness growth.

Furthermore, CROs and CDMOs have witnessed significant growth during the past few years as most of the pharmaceutical companies are opting to outsource their drug development and manufacturing activities to these outsourcing companies. Building and maintaining internal capabilities for all aspects of personalized medicine, from development to manufacturing, requires several resources and investments. Therefore, outsourcing these activities can allow companies to access specialized expertise, infrastructure, and resources according to their needs, thereby offering a cost-effective solution. Moreover, the complexity and risk associated with the development of personalized solutions, such as failures in the preclinical and clinical phases, offer a significant risk factor, while CROs can handle the complexities of later-stage development and manufacturing, allowing companies to streamline their operations and enhance their efficiency.

The awareness about personalized medicine has significantly increased in recent years owing to its several benefits, such as reducing trial and error prescribing, helping in avoiding adverse drug reactions, and shifting the medical importance from prevention to reaction. Personalized medicine offers the ability to use molecular markers that can indicate disease risk or presence even before clinical signs and symptoms appear, allowing for early treatments of diseases and thereby improving patient outcomes. Similarly, the patient's non-compliance with offered treatment and medication can lead to adverse health effects such as Adverse Drug Reactions (ADR), which have been on a significant rise in past years. Thus, increasing cases of ADRs would boost the demand for better treatment options among people further driving the demand for personalized medicine. For instance, according to an article published by the National Institute of Health (NIH) in January 2024, there were around 1.25 million serious adverse effects and approximately 175,000 deaths were recorded in the U.S. in 2022.

Global Personalized Medicine Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global personalized medicine outsourcing market report based on phase, application, service, type, end use, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Clinical
• Phase I
• Phase II
• Phase III
• Phase IV
• Preclinical
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Oncology
• Rare Diseases
• Infectious Diseases
• Others
• Service Outlook (Revenue, USD Million, 2018 - 2030)
• Contract Manufacturing
• Contact Development
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Inhibitor Drugs
• Monoclonal Antibodies
• Cell & Gene Therapy
• Other Therapeutic Products
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical Companies
• Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information analysis
  • 1.3.2. Data validation & publishing
  • 1.3.3. Information Procurement
  • 1.3.4. Primary Research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Research Models
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Personalized Medicine Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic and rare diseases
    • 3.2.1.2. Increasing awareness about the benefits of personalized medicine
    • 3.2.1.3. Increasing application of personalized medicine in various diseases
    • 3.2.1.4. Requirement of specialized expertise for personalized medicine development and manufacturing
  • 3.2.2. Market restraints analysis
    • 3.2.2.1. Data privacy concerns
    • 3.2.2.2. Compliance issues with outsourcing
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's five forces analysis
  • 3.3.2. PESTEL analysis
  • 3.3.3. COVID-19 impact analysis

Chapter 4. Personalized Medicine Outsourcing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Personalized Medicine Outsourcing Market Product Movement Analysis
• 4.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Clinical
  • 4.4.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Phase I
    • 4.4.2.1. Phase I Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Phase II
    • 4.4.3.1. Phase II Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Phase III
    • 4.4.4.1. Phase III Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Phase IV
    • 4.4.5.1. Phase IV Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 4.5. Preclinical
  • 4.5.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Personalized Medicine Outsourcing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Personalized Medicine Outsourcing Market Application Movement Analysis
• 5.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.5. Rare Diseases
  • 5.5.1. Rare Diseases Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Personalized Medicine Outsourcing Market: Service Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Personalized Medicine Outsourcing Market Service Movement Analysis
• 6.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 6.4. Contract Manufacturing
  • 6.4.1. Contract Manufacturing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 6.5. Contact Development
  • 6.5.1. Contact Development Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Personalized Medicine Outsourcing Market: Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Personalized Medicine Outsourcing Market Type Movement Analysis
• 7.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 7.4. Inhibitor Drugs
  • 7.4.1. Inhibitor Drugs Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.5. Monoclonal Antibodies
  • 7.5.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.6. Cell & Gene Therapy
  • 7.6.1. Cell & Gene Therapy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Personalized Medicine Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Personalized Medicine Outsourcing Market End Use Movement Analysis
• 8.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Pharmaceutical Companies
  • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 8.5. Biotechnology Companies
  • 8.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 9. Personalized Medicine Outsourcing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.7. Norway
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Competitive scenario
    • 9.5.8.3. Regulatory framework
    • 9.5.8.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.9. Denmark
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Competitive scenario
    • 9.5.9.3. Regulatory framework
    • 9.5.9.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Competitive scenario
    • 9.6.4.3. Regulatory framework
    • 9.6.4.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Competitive scenario
    • 9.6.5.3. Regulatory framework
    • 9.6.5.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Competitive scenario
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Competitive scenario
    • 9.6.7.3. Regulatory framework
    • 9.6.7.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Competitive scenario
    • 9.8.2.3. Regulatory framework
    • 9.8.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Competitive scenario
    • 9.8.3.3. Regulatory framework
    • 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Competitive scenario
    • 9.8.4.3. Regulatory framework
    • 9.8.4.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key country dynamics
    • 9.8.5.2. Competitive scenario
    • 9.8.5.3. Regulatory framework
    • 9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
  • 10.1.1. Market Leaders
  • 10.1.2. Emerging Players
• 10.2. Company Market Position Analysis, 2024
• 10.3. Company Profiles
  • 10.3.1. Parexel International (MA) Corporation
    • 10.3.1.1. Company overview
    • 10.3.1.2. Financial performance
    • 10.3.1.3. Service benchmarking
    • 10.3.1.4. Strategic initiatives
  • 10.3.2. Syneos Health
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Service benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. Catalent, Inc
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Service benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. ICON
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Service benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Lonza
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Service benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Syngene International Limited
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Service benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. HCL Technologies Limited
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Service benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Infosys Limited
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Service benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Fujirebio
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Service benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Aurigene Pharmaceutical Services Ltd.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Service benchmarking
    • 10.3.10.4. Strategic initiatives